Clinical trial · no report yet · Phase 2/Phase 3
B-FAST
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- NCT03178552 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib; Atezolizumab; Pemetrexed; Cisplatin; Carboplatin; Gemcitabine; Entrectinib; Cobimetinib; Vemurafenib; Bevacizumab; Divarasib; Docetaxel
- Arms
- Cohort A: Alectinib 600 Milligrams (mg) · Experimental
- Cohort B: Dose Finding Phase (DFP) Alectinib · Experimental
- Cohort B: Dose Expansion Phase (DEP) Alectinib · Experimental
- Cohort C: Atezolizumab 1200 mg · Experimental
- Cohort C: Pemetrexed, Cisplatin or Carboplatin · Active comparator
- Cohort C: Gemcitabine, Cisplatin or Carboplatin · Active comparator
- Cohort D: Entrectinib 600 Milligrams (mg) · Experimental
- Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib · Experimental
- Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed · Experimental
- Cohort G: Divarasib or Docetaxel · Experimental
- Cohort Z: Natural History Cohort · No intervention
- Enrollment
- 1,000 (estimated)
- Primary outcomes
- Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
- Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1
- Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1
- Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1
- Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1
- Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1
- Cohort G: Incidence of Adverse Events (AEs)
- Sponsor
- Hoffmann-La Roche
- Start
- Sep 22, 2017
- Primary completion
- Jun 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03178552 · updated Sep 3, 2026
Publications
linked from the registry- Mayerhoefer ME, Kienzle A, Woo S, Vargas HA. Update on Liquid Biopsy. Radiology. 2025 Jun;315(3):e241030. doi: 10.1148/radiol.241030. PubMed 40525978
- Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, Dziadziuszko R. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. Nat Med. 2024 Jul;30(7):1923-1932. doi: 10.1038/s41591-024-03008-4. Epub 2024 Jun 19. PubMed 38898120
- Wang HY, Ho CC, Lin YT, Liao WY, Chen CY, Shih JY, Yu CJ. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. JCO Precis Oncol. 2024 Jan;8:e2300314. doi: 10.1200/PO.23.00314. PubMed 38190582
- Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22. PubMed 35995953